Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease

An Unusual “OR” Gate for Allosteric Regulation of Mammalian Transglutaminase 2 in the Extracellular Matrix

(2021) Arek V. Melkonian et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease

(2021) Detlef Schuppan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Solution-phase synthesis of the fluorogenic TGase 2 acyl donor Z-Glu(HMC)-Gly-OH and its use for inhibitor and amine substrate characterisation

(2020) Robert Wodtke et al.   ANALYTICAL BIOCHEMISTRY

Evidence that pathogenic transglutaminase 2 in celiac disease derives from enterocytes

(2020) Rasmus Iversen et al.   GASTROENTEROLOGY

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors

(2020) Linlin Zhang et al.   SCIENCE

10 years into the resurgence of covalent drugs

(2020) Elena De Vita   Future Medicinal Chemistry

Current and emerging therapies for coeliac disease

(2020) Laura Kivelä et al.   Nature Reviews Gastroenterology & Hepatology

Coeliac disease

(2019) Katri Lindfors et al.   Nature Reviews Disease Primers

Novel inhibitor ZED3197 as potential drug candidate in anticoagulation targeting coagulation FXIIIa (F13a)

(2019) Ralf Pasternack et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

The diamond anniversary of tissue transglutaminase: a protein of many talents

(2018) William P. Katt et al.   DRUG DISCOVERY TODAY

The Curtius rearrangement: mechanistic insight and recent applications in natural product syntheses

(2018) Arun K. Ghosh et al.   ORGANIC & BIOMOLECULAR CHEMISTRY

Transglutaminase diseases: from biochemistry to the bedside

(2018) Laszlo Lorand et al.   FASEB JOURNAL

The roles of MHC class II genes and post-translational modification in celiac disease

(2017) Ludvig M. Sollid   IMMUNOGENETICS

Determining Partition Coefficient (Log P), Distribution Coefficient (Log D) and Ionization Constant (pKa) in Early Drug Discovery

(2016) Sonali S. Bharate et al.   COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING

P2X7 receptor activation regulates rapid unconventional export of transglutaminase-2

(2015) M. Adamczyk et al.   JOURNAL OF CELL SCIENCE

Igs as Substrates for Transglutaminase 2: Implications for Autoantibody Production in Celiac Disease

(2015) R. Iversen et al.   JOURNAL OF IMMUNOLOGY

Interactions Among Secretory Immunoglobulin A, CD71, and Transglutaminase-2 Affect Permeability of Intestinal Epithelial Cells to Gliadin Peptides

(2012) Corinne Lebreton et al.   GASTROENTEROLOGY

Evidence that HLA-DQ9 confers risk to celiac disease by presence of DQ9-restricted gluten-specific T cells

(2012) Michael Bodd et al.   HUMAN IMMUNOLOGY

Activation of Extracellular Transglutaminase 2 by Thioredoxin

(2011) Xi Jin et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The resurgence of covalent drugs

(2011) Juswinder Singh et al.   NATURE REVIEWS DRUG DISCOVERY

The Use of Biorelevant Dissolution Media to Forecast the In Vivo Performance of a Drug

(2010) Sandra Klein   AAPS Journal

What is modulating solubility in simulated intestinal fluids?

(2010) Giorgio Ottaviani et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Redox Regulation of Transglutaminase 2 Activity

(2010) Jorunn Stamnaes et al.   JOURNAL OF BIOLOGICAL CHEMISTRY